(NASDAQ: PVLA) Palvella Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 4.08%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 15.96%.
Palvella Therapeutics's earnings in 2025 is -$26,608,000.On average, 8 Wall Street analysts forecast PVLA's earnings for 2025 to be -$35,363,279, with the lowest PVLA earnings forecast at -$37,602,861, and the highest PVLA earnings forecast at -$30,967,062. On average, 8 Wall Street analysts forecast PVLA's earnings for 2026 to be -$36,898,360, with the lowest PVLA earnings forecast at -$45,344,627, and the highest PVLA earnings forecast at -$27,096,179.
In 2027, PVLA is forecast to generate -$54,988,654 in earnings, with the lowest earnings forecast at -$94,338,942 and the highest earnings forecast at -$39,593,601.